Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

30.46
-1.6300-5.08%
Post-market: 30.460.00000.00%16:34 EDT
Volume:693.96K
Turnover:21.38M
Market Cap:2.67B
PE:-23.71
High:32.05
Open:31.90
Low:30.36
Close:32.09
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.49
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2849
EPS(LYR):-1.2849
ROE:-10.92%
ROA:-8.92%
PB:2.61
PE(LYR):-23.71

Loading ...

IDEAYA Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 06

IDEAYA Biosciences Presents at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

IDEAYA Biosciences (IDYA): Valuation Check After Key Phase 2/3 Milestone for Darovasertib in Uveal Melanoma

Simply Wall St.
·
Dec 26, 2025

IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress

Simply Wall St.
·
Dec 16, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
Dec 11, 2025

IDEAYA Biosciences Completes Enrollment in Pivotal Phase 2/3 Trial of Darovasertib and Crizotinib for Metastatic Uveal Melanoma

Reuters
·
Dec 11, 2025

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination With Crizotinib in First-Line Hla*a2-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
Dec 11, 2025

IDEAYA Biosciences Inc - Topline Data Expected in 1Q 2026

THOMSON REUTERS
·
Dec 11, 2025

IDEAYA Biosciences Submits US FDA Investigational New Drug Application for Potential Cancer Therapy

MT Newswires Live
·
Dec 10, 2025

BRIEF-Ideaya Biosciences Announces Ind Submission For Ide574

Reuters
·
Dec 10, 2025

IDEAYA Biosciences- Phase 1 Dose Escalation Trial of Monotherapy Ide574 Expected to Begin in 1Q 2026

THOMSON REUTERS
·
Dec 10, 2025

IDEAYA Biosciences Announces Ind Submission for Ide574, a Potential First-in-Class Kat6/7 Dual Inhibitor for Breast and Lung Cancers

THOMSON REUTERS
·
Dec 10, 2025

IDEAYA Biosciences Inc - Preclinical Data for Ide574 to Be Presented in 1H 2026

THOMSON REUTERS
·
Dec 10, 2025

Is GSK’s Exit and IDE034’s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences (IDYA)?

Simply Wall St.
·
Dec 09, 2025

Taking Stock of IDEAYA Biosciences (IDYA) Valuation After FDA Clears IDE034 for Phase 1 Trial

Simply Wall St.
·
Dec 07, 2025

IDEAYA Biosciences Inc - to Evaluate Strategic Options for Programs in 2026 - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

IDEAYA Biosciences:on December 4, Glaxosmithkline Intellectual Property Terminated Collaboration Agreement With IDEAYA Biosciences - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

IDEAYA and Biocytogen Receive FDA Clearance for IND Application of IDE034

Reuters
·
Dec 05, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

Sector Update: Health Care Stocks Decline Pre-Bell Monday

MT Newswires Live
·
Dec 01, 2025